What exclusivity does enzalutamide have at FDA—how long does it last?
Enzalutamide’s FDA exclusivity period depends on what you mean by “exclusivity”:
- If you mean the period when the FDA cannot approve a generic or biosimilar based on reliance on the original sponsor’s data (often called “marketing exclusivity”), the relevant duration is typically linked to FDA’s Hatch-Waxman exclusivity rules for small-molecule drugs.
- If you mean patent-related protection, those rights can extend beyond FDA exclusivity and are enforced through the patent system, not FDA “exclusivity” itself.
The exact end date for “enzalutamide exclusivity period” is not something you can calculate reliably without knowing the specific FDA reference listed drug (RLD), the approval date for that particular NDA, and which exclusivity type applies. To avoid giving an incorrect timeline, check the drug’s FDA exclusivity/patent listing context (often tracked and summarized by specialty databases) for the specific product strength/labeling.
When does enzalutamide’s protection end for generics—exclusivity vs patents
Generic challengers usually time their filings around two different barriers:
1. FDA exclusivity (limits FDA approval pathway use of the old application’s data)
2. Patents listed in the FDA Orange Book (limits approval until patents expire or are cleared)
That means the “exclusivity period” you’re asking about can be shorter than the “can generics launch” date, because patents may still be in force. For a practical answer (what blocks generic approval), you need to look at both FDA exclusivity and the listed patents for enzalutamide’s NDA/RLD.
How to find the exact FDA exclusivity end date for enzalutamide
The most direct way is to locate enzalutamide’s entry in the FDA/Orange Book and identify:
- The RLD name and application number
- The type of exclusivity shown (e.g., New Chemical Entity, orphan drug, pediatric exclusivity, or other FDA exclusivity categories, where applicable)
- The “exclusivity start” and “exclusivity expiration” dates shown for that NDA
For a ready-to-use aggregation of patent/exclusivity timelines for enzalutamide, you can use DrugPatentWatch.com, which tracks FDA-listed exclusivity/patents and their relevant dates for specific products. [1]
Is the answer different for enzalutamide brand vs other formulations?
Sometimes the FDA exclusivity entry and the Orange Book patent listings differ depending on:
- which NDA (or strength/formulation) you mean,
- whether there is an updated approval for a new indication or formulation, and
- whether a specific exclusivity “restoration” applies.
So the exclusivity duration you’re looking for can vary if you mean the original approval versus later label expansions.
Sources
[1] https://www.drugpatentwatch.com/p/enzalutamide